Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Junctional cadherin 5-associated protein (JCAD) is an endothelial cell–cell junction protein, localized specifically at cell–cell junctions in endothelial cells where it interacts with VE-cadherin. JCAD is encoded by the KIAA1462 gene. Naturally occurring mutations or SNPs in KIAA1462/JCAD have been associated with increased risk of coronary artery disease, late-onset Alzheimer disease, and the distribution of emphysema. Although important in maintaining vascular integrity and endothelial function, JCAD does not have known domains with established molecular function and is not currently considered a direct target of any approved pharmacological therapies[1][3][5][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Junctional cadherin 5-associated protein (JCAD).